...AbbVie's CGRP inhibitor Qulipta for the prevention of episodic migraine, with analysts already calling the drug a blockbuster-to-be. Qulipta will have to face off against Biohaven's Nurtec ODT, the first oral CGRP inhibitor approved in the migraine space. For migraine prevention, Nurtec holds covered or better status for 77% of all insured lives under the pharmacy benefit, and is not covered for 19.2% of lives.
SOURCE: MMIT Analytics, as of 10/6/21
No comments:
Post a Comment